文章基本信息

标题：Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients
本地全文：下载
作者：Mehrdad Farrokhi ; Ali Amani Beni ; Masoud Etemadifar 等
期刊名称：INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE
印刷版ISSN：2008-7802
出版年度：2015
卷号：6
页码：125
DOI：10.4103/2008-7802.172539
语种：English
出版社：ISFAHAN UNIVERSITY OF MEDICAL SCIENCES
摘要：Background: While many studies have previously focused on fingolimod's effect on immune cells, the effect it has on circulating and local central nervous system platelets (Plts) has not yet been investigated. This study will elucidate what effects fingolimod treatment has on multiple sclerosis (MS) patients’ plasma Plt levels. In addition, it will propose possible reasoning for these effects and suggest further investigation into this topic. Methods: This quasi-experimental study used patients from the Isfahan Multiple Sclerosis Society to produce a subject pool of 80 patients, including 14 patients who ceased fingolimod use due to complications. The patients had their blood analyzed to determine Plt levels both 1-month prior to fingolimod treatment and 1-month after fingolimod treatment had been started. Results: The mean level of Plts before initiation of fingolimod therapy (Plt1) among these MS patients was 256.53 ± 66.26. After 1-month of fingolimod treatment, the Plt level yielded an average of 229.96 ± 49.67 (Plt2). This number is significantly lower than the average Plt count before treatment ( P < 0.01). Conclusions: MS patients taking oral fingolimod treatment may be at risk for side-effects caused by low Plt levels. This may not be a factor for patients with higher or normal Plt levels. However, a patient with naturally low Plt levels may experience a drop below the normal level and be at risk for excessive bleeding. In addition to these possible harmful side-effects, the decreased Plt population may pose positive effects for MS patients.
关键词：Fingolimod; multiple sclerosis; platelet